{"id":23954,"date":"2026-02-25T07:19:13","date_gmt":"2026-02-25T07:19:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/23954\/"},"modified":"2026-02-25T07:19:13","modified_gmt":"2026-02-25T07:19:13","slug":"novo-and-chinese-partner-report-strong-weight-loss-results","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/23954\/","title":{"rendered":"Novo and Chinese partner report strong weight loss results"},"content":{"rendered":"

\"\"<\/p>\n

Novo Nordisk and China\u2019s United Laboratories International Holdings have announced promising results from a clinical trial of a new experimental obesity drug, the company reports in a press release<\/a>.<\/p>\n

In a phase 2 study involving 205 Chinese patients with overweight or obesity, participants lost up to 19.7 percent of their body weight after 24 weeks of treatment. By comparison, patients who received a placebo lost about 2 percent.<\/p>\n

\u201cWe are very encouraged by these data from the trial in China,\u201d said Martin Holst Lange, executive vice president and head of R&D at Novo Nordisk. \u201cWe look forward to reporting data from a global trial next year.\u201d<\/p>\n

After stock slump, new China data brings relief<\/p>\n

The announcement comes just days after Novo\u2019s obesity candidate CagriSema delivered weaker-than-expected results in a head-to-head study against US rival Eli Lilly. The setback sent Novo shares down more than 15 percent.<\/p>\n

The drug candidate, known as UBT251, works by targeting three hormones that help regulate appetite, blood sugar and metabolism. This makes it part of a new generation of so-called \u201ctriple agonist\u201d treatments in the global race to develop more effective weight-loss medicines.<\/p>\n

According to the companies, the treatment was generally well tolerated. The most common side effects were mild to moderate digestive issues.<\/p>\n

Under a 2025 agreement, Novo Nordisk holds the rights to develop and market the drug outside China, while its Chinese partner retains regional rights.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk and China\u2019s United Laboratories International Holdings have announced promising results from a clinical trial of a…\n","protected":false},"author":2,"featured_media":23955,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[14738,15836,694,272,280],"class_list":{"0":"post-23954","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-cagrisema","9":"tag-chinas-united-laboratories-international-holdings","10":"tag-medicine","11":"tag-novo-nordisk","12":"tag-weight-loss"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/23954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=23954"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/23954\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/23955"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=23954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=23954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=23954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}